Reply to Chemical Risk Factors of Primary Liver Cancer: A Short Comment [Response To Letter]

Adam Barsouk¹

Krishna Chaitanya Thandra²

Kalyan Saginala³

Prashanth Rawla⁴

¹Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, PA, 19107, USA;

²Department of Pulmonary and Critical Care Medicine, Sentara Virginia Beach General Hospital, Virginia Beach, VA, USA; ³Plains Regional Medical Group Internal Medicine, Clovis, NM, 88101, USA; ⁴Department of Medicine, Sovah Health, Martinsville, VA, 24112, USA

Dear editor

We would like to thank Dr. Laraib Ghanghro for his insightful feedback and for bringing these compounds and their metabolites to our attention. Our understanding of HCC pathogenesis is always changing and contributions like his are essential to keeping physicians, researchers and public health officials informed.

Disclosure

All the authors declare no conflict of interest in this communication.

Correspondence: Prashanth Rawla
Department of Internal Medicine/
Hospitalist, SOVAH Health, 320 Hospital
Dr, Martinsville, VA, 24115, USA
Email rawlap@gmail.com

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Hepatic Medicine: Evidence and Research 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Hepatic Medicine: Evidence and Research editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Hepatic Medicine: Evidence and Research

Dovepress

Publish your work in this journal

Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access journal covering all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease; Investigation and treatment of hepatic disease; Pharmacology of drugs used for the

treatment of hepatic disease. Issues of patient safety and quality of care will also be considered. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/hepatic-medicine-evidence-and-research-journal>

<https://doi.org/10.2147/HMER.S352746>